Cadonilimab (PD-1/CTLA-4) Receives FDA Clearance for Global Phase III First-Line Gastric Cancer Trial Versus Nivolumab

HONG KONG, Dec. 11, 2025 /PRNewswire/ — Akeso, Inc. (9926.HK) (“Akeso” or the “Company”) announced FDA approval to initiate COMPASSION-37/AK104-311 trial, a global multicenter…